On Thursday, January 22nd., in-Pharma Technologist published an article on the advent of injectable systems. The article included comments from Alan Shortall. Unfortunately the article was too long to post on Yahoo.
You may find the article by searching "Pharma turning to injectable systems to protect biologics, says Unilife"
I agree with virtually all of the negative sentiment expressed about Zacks. Pragmatically though, if we feel discouraged when they publish an unsupported negative article, it's not wrong to feel encouraged when they publish a positive one. "Good news" comes in all forms. At a time when we are trying to breakthrough resistance levels, it seems to me that positive publicity should be welcomed. Their latest article is already up on Nasdaq and Yahoo news and, by Monday, it will likely be found on many more news feeds. Their suggestion that the upward move could definitively #$%$ for several weeks may persuade some investors to buy in, pushing the stock higher. Certainly it will get the attention of many Zacks paid members, many of whom follow their recommendations closely. That said, again, I am not a fan of Zacks.
Best I can figure, here are the latest recommendations:
Griffin - 15.50
Jefferies Goup - 9.00
LeeRink Schwan - 8.00
Cantor Fitzgerald - 8.00
Ladenburg Thalmann - 5.00
"Analyst Rating" doesn't include Griffin. Their consensus is $7.33
"Street Insider includes Griffin, but at their previous PT of $13.50, for a consensus of $8.88
If you increase Griffin to the current PT of 15.50, Street Insider's PT would increase to 9.10
Schmagecky, You're not far off. Zack's "product" are their recommendations and the ROI attainable if you were to duplicate them. Members have access to the additions to their daily recommendations before the market opens. They move in and out of stocks often. One morning you may find that XYZ Corp. has been raised from Neutral to a Strong Buy. Three days later it may shift back to Neutral and a day after that to a Sell. Essentially they attempt to identify and capitalize on short term trends. This approach really doesn't lend itself to the long-term investor, as they are not immersed in the growth story.
Their approach can work. In the few months I was a paid member I did make some money, but found that I didn't enjoy the frenetic fluidity of their trading approach.
The following article was published today, January 23rd, by Zacks Equity Investments (yes, the same folks who said it was overbought and recommended a strong sell)
Title: "Can the Trend Continue for Unilife (UNIS)?"
"Article: Investors certainly have to be happy with Unilife Corp and it's short term performance. After all, the stock has jumped 38.9% in the past 4 weeks, and it's also above it's 20 Day Simple Moving Average as well. This is certainly a good trend, but investors are probably asking themselves, can this positive trend continue for UNIS?"
"While we can never know for sure, it is pretty encouraging that estimates for UNIS have moved higher in the past few weeks, meaning that analyst sentiment is moving in the right way. Plus, the stock actually has a Zacks Rank No. 2 (BUY), so the recent move higher for this company may definitely continue over the next few weeks."
Itsa1188, I too use Fidelity. If you examine Valuengine's past UNIS recommendations, they have actually done a poor job during the past year or so. In fact, had an investor taken a contrarian approach and bought shares each time they downgraded UNIS and sold each time they upgraded they would have made real money. This is reinforced by their StarLine rating of 50 (out of 100), equating to the flip of a coin. Zack's only scored 45! Ironic that both firms charge membership fees to access their recommendations!
misterbodacious... In the coming weeks it will become apparent that the shorts have backed themselves into a corner. Normally when bloggers like yourself fail spectacularly, they either disappear or return with a new name. I'd like to give you a helping hand by suggesting a new name.
Just change "misterbodacious" to "misterinefficacious." There, that was easy!
Merriam Webster (def.) "Lacking the power to produce a desired effect"
Minnie, When I first began investing in earnest I made the mistake of subscribing to Zacks for a couple of months. In addition to being inundated by their marketing emails on a daily basis, I found that, basically I was just paying for a buy/sell/hold recommendation. As you have mentioned, they provide very little analysis. You can get much more information from many sites like Stoxline at no cost.
The Lisa auto- injector has no peers. It is the only reusable auto- injector on the market, and as we discussed in our most recent Unilife update report, it is Bluetooth enabled. That feature, which permits doctors to follow their patients’ compliance with the prescribed drug regimen, will distinguish Humira from the competition. And similar HIPPA- compliant data provided to AbbVie should be instrumental in securing favorable reimbursement terms even in a more competitive marketplace. Patients will probably also prefer the Lisa to any other device since it is customized to deliver a drug at an optimal rate to minimize pain.
We have updated our financial projections to include a commercial supply agreement with AbbVie. That analysis has led us to raise our 12-month price target for Unilife to $15.50 per share. UNIS stock has our BUY recommendation.
NOTE: The complete report "A Major Deal Close at Hand", dated January 20th, as well as a second report "Unilife Prepares for Commercialization" can be read on the Griffin Securities website, under the "Research"/"Small Cap" link.
The second report "Unilife Prepares for Commercialization" addresses the advantages offered through Bluetooth technology.
A Major Deal Close at Hand
Keith A. Markey, Ph.D, MBA, Griffin Securities
AbbVie commits to form a global partnership for Unilife devices. The drug company will pay $5 million to form and enter into a contract for exclusive access to the Lisa™ auto-injector and the Finesse™ syringe in the autoimmune disease market. The most important agent is Humira®, which generates about $12.5 billion in annual sales for AbbVie. Since the patent on Humira expires in late 2016, we believe launch of the drug in Unilife’s syringe and auto-injector will commence this calendar year. As a result, completion of the exclusive commercialization contract is likely to be completed in Unilife’s fiscal 2015 (ends June 30th). Note that the contract will probably come with a sizable upfront exclusivity fee, much as the Sanofi agreement provided for exclusive rights to the Finesse syringe for Lovenox®
Unilife’s technology is aligned with AbbVie’s strategic plan for protecting its autoimmune franchise. It should help fend off competition to Humira after the patent has expired and aid in launching therapies now in development. Important elements of the Humira strategy are a new formulation of the drug and device
enhancements that differentiate it from biosimilars.
The Finesse syringe stands out in the syringe market for the protection it affords against accidental needlesticks via a simple user- controlled needle retraction technology.
Keep reading "Writer's" posts on Hot Copper... After writing the earlier post, "Writer" has posted follow-up information on the AbbieVie announcement and its potential implications, as well as the updated report from Keith Markey of Griffin Securities.
I'm sure most of the longs here visit Hot Copper on a regular basis. However, for those who might not be familiar, Google "Hot Copper", then go to "UNS" and read "Writer's" post "Unilife partners with AbbieVie." Outstanding recap of the im0plications of today's 8K announcement! It just keeps getting better!!!!!
You shorts have a "mantra" for all seasons. If I counted the number of times I have read that tired, old canard in the last two and a half years.Lets see, "we're overbought", we're going to go bankrupt", we'll run out of money", we'll need a dilution, bla, bla, bla. However, I notice that with the signing of multiple, lucrative, long-term contracts and the hiring of top-tier executives, you hardly have any slogans left to use. Revenue will come. More deals will come. We know it, you know it.
If you could only fall back on some of your time-tested, well-used inflammatory themes, i.e. lawsuits, personal attacks on Alan Shortall, FDA inspections, falsifying shipments etc. But alas, John Ryan seems to have put an end to those.
So, here you are. Beating on the table about running out of money while Unilife racks up one deal after another... and they're just beginning.
Yes, no doubt that's why JPM just upped their position to 10%.... but, hey, you are probably more qualified that they are. Right? Jefferies Group - $9.00, Leerink Schwann - $8.00, Cantor Fitzgerald - $8.00, Griffin Securities - $13.50, Ladenburg Thallman - $5.00. It's tough, but I'm going to have to go with the brokers.
Istalongroad75, Have you signed up for IR Email alerts? I assume you have. If you don't get the email, maybe you might want to revisit the "Email Alert Subscription" page to make sure all options you want are checked. Then again, late emails do happen.